Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Summary

This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH). MASH is more advanced stage of a broader liver disease, MASLD. MASLD is a liver condition caused by too much fat building up in the liver. This can lead to liver scarring and inflammation and can reduce the liver's ability to keep the body healthy. Cell death-inducing DFFA-like effector B (CIDEB) is a protein made by liver cells that helps the liver to store fat.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Metabolic Dysfunction-Associated Steatotic Liver Disease
• MASLD

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Regeneron Pharmaceuticals

Last updated on ClinicalTrials.gov

November 2, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites